|Bid||0.00 x 800|
|Ask||0.00 x 1400|
|Day's range||11.23 - 11.79|
|52-week range||5.42 - 16.40|
|Beta (5Y monthly)||1.51|
|PE ratio (TTM)||14.56|
|Earnings date||30 Jul 2020 - 03 Aug 2020|
|Forward dividend & yield||1.28 (11.12%)|
|Ex-dividend date||13 May 2020|
|1y target est||12.08|
Ladies and gentlemen, thank you for standing by, and welcome to the Hercules Capital Q1 2020 earnings conference call. With us on the call today from Hercules are Scott Bluestein, CEO and chief investment officer; and Seth Meyer, CFO. Hercules first-quarter 2020 financial results were released just after today's market close and can be accessed from Hercules Investor Relations section at htgc.com.
Hercules Tech (HTGC) delivered earnings and revenue surprises of 2.78% and 5.50%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Hercules Capital, Inc. (NYSE: HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced its financial results for the first quarter ended March 31, 2020.
Hercules Capital, Inc. (NYSE: HTGC) ("Hercules" or the "Company"), the largest and leading specialty finance provider to innovative, venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, is pleased to announce that its Board of Directors has declared a first quarter 2020 cash distribution of $0.32 per share. The following shows the key dates of the first quarter 2020 distribution payment:
Hercules Tech (HTGC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Hercules Capital, Inc. (NYSE: HTGC) ("Hercules" or the "Company"), will conduct both its 2020 Annual Meeting of Stockholders and its Special Meeting of Stockholders by virtual meeting on Friday, June 12, 2020 at 9:00 a.m. and 10:00 a.m. (Pacific Time), respectively. The proxy statement for each meeting will be mailed separately on or about April 29, 2020 to shareholders of record as of April 20, 2020.
Hercules Capital, Inc. (NYSE: HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that it has scheduled its first quarter 2020 financial results conference call for Monday, May 4, 2020, at 2:00 p.m. PT (5:00 p.m. ET). Hercules will release its financial results after market close that same day.
The team at Hercules Capital, Inc. (NYSE: HTGC) ("Hercules" or the "Company") is working collectively with our employees, shareholders, stakeholders, bondholders, rating agencies, portfolio companies, and our venture capital and private equity sponsors to navigate the significant challenges created by the unprecedented COVID-19 (Coronavirus) pandemic. We are vigilantly monitoring this evolving situation and have implemented actions to keep our employees safe while also managing the continuity of our business. Our thoughts and prayers are with everyone who has been impacted by these events.
Hercules Tech (HTGC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Hercules Capital's (HTGC) results for the fourth quarter of 2019 are expected to reflect favorable impacts of an anticipated rise in investment income.
ChemoCentryx, Inc., (CCXI) today announced that the Company has secured a credit facility of up to $100 million provided by Hercules Capital, Inc. (HTGC), a leader in customized financing for companies in life sciences and technology-related markets. “Through this non-dilutive credit mechanism, we have options to strengthen our robust balance sheet as we advance avacopan towards commercialization in ANCA vasculitis,” said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx. The $100 million credit facility from Hercules Capital comprises three tranches over the next two years to be drawn at ChemoCentryx’s discretion as follows: the first tranche of $40 million is available through December 2020, $20 million of which would be available upon the submission of the avacopan New Drug Application (NDA) for the treatment of ANCA vasculitis; the second tranche of $30 million is available through December 2021 upon NDA approval of avacopan for the treatment of ANCA vasculitis (NDA Approval); the remaining $30 million is available through December 2022, subject to certain conditions.
Low-interest (3-month LIBOR plus 3%) loan facility from Sumitomo Dainippon Pharma increased to allow repayment of pre-existing debtHiroshi Nomura, President, CEO, and.
Hercules Capital (HTGC) remains well-positioned for growth based on its strong liquidity position, improving economy and robust loan originations.